Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abu Eid, Sameer | - |
dc.contributor.author | Adams, Michael | - |
dc.contributor.author | Scherer, Thomas | - |
dc.contributor.author | Torres-Gómez, Héctor Manuel | - |
dc.contributor.author | Hackl, Martina Theresa | - |
dc.contributor.author | Kaplanian, Mairam | - |
dc.contributor.author | Riedl, Rainer | - |
dc.contributor.author | Luger, Anton | - |
dc.contributor.author | Fürnsinn, Clemens | - |
dc.date.accessioned | 2018-02-14T07:55:38Z | - |
dc.date.available | 2018-02-14T07:55:38Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0014-2999 | de_CH |
dc.identifier.issn | 1879-0712 | de_CH |
dc.identifier.uri | https://digitalcollection.zhaw.ch/handle/11475/2761 | - |
dc.description.abstract | Emodin is found in remedies from Traditional Chinese Medicine. Since antihyperglycaemic action was observed in rodents, non-scientific sources advertise emodin intake as a natural cure for diabetes. Emodin was admixed to high fat-food of obese mice at two doses (2 and 5 g/kg; daily emodin uptake 103 and 229 mg/kg). Comparison was made to ad libitum fed and to food restricted control groups, the latter showing the same weight gain as the corresponding emodin-treated groups. Emodin blunted food intake by 6% and 20% for the low and high dose, which was accompanied by proportionate reductions in weight gain. Emodin reduced blood glucose relative to freely feeding controls, but comparison to weight-matched controls unmasked deterioration, rather than improvement, of basal glycaemia (mmol/l: fed ad libitum, 9.5±0.4; low emodin, 9.4±0.3, weight-matched, 8.2±0.3; high emodin, 7.2±0.4, weight-matched, 6.1±0.3; P<0.01, emodin vs weight-matched) and glucose tolerance (area under the curve, min*mol/l: fed ad libitum, 2.01±0.08; low emodin, 1.97±0.12, weight-matched, 1.75±0.03; high emodin, 1.89±0.07, weight-matched, 1.65±0.05; P<0.0002, emodin vs weight-matched). An insulin tolerance test suggested insulin desensitisation by prolonged emodin treatment. Furthermore, a single oral emodin dose did not affect glucose tolerance in obese mice, whereas intravenous injection in rats suggested a potential of emodin to acutely impair insulin release. Our results show that the antihyperglycaemic action of emodin as well as associated biochemical alterations could be the mere consequences of a spoilt appetite. Published claims of antidiabetic potential via other mechanisms evoke the danger of misuse of natural remedies by diabetic patients. | de_CH |
dc.language.iso | en | de_CH |
dc.publisher | Elsevier | de_CH |
dc.relation.ispartof | European Journal of Pharmacology | de_CH |
dc.rights | Licence according to publishing contract | de_CH |
dc.subject | Glucose | de_CH |
dc.subject | Emodin | de_CH |
dc.subject | Diabetes | de_CH |
dc.subject.ddc | 572: Biochemie | de_CH |
dc.subject.ddc | 615: Pharmakologie und Therapeutik | de_CH |
dc.title | Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents | de_CH |
dc.type | Beitrag in wissenschaftlicher Zeitschrift | de_CH |
dcterms.type | Text | de_CH |
zhaw.departement | Life Sciences und Facility Management | de_CH |
zhaw.organisationalunit | Institut für Chemie und Biotechnologie (ICBT) | de_CH |
dc.identifier.doi | 10.1016/j.ejphar.2017.01.022 | de_CH |
zhaw.funding.eu | No | de_CH |
zhaw.originated.zhaw | Yes | de_CH |
zhaw.pages.end | 84 | de_CH |
zhaw.pages.start | 77 | de_CH |
zhaw.publication.status | publishedVersion | de_CH |
zhaw.volume | 798 | de_CH |
zhaw.publication.review | Peer review (Publikation) | de_CH |
zhaw.webfeed | CC Drug Discovery | de_CH |
Appears in collections: | Publikationen Life Sciences und Facility Management |
Files in This Item:
There are no files associated with this item.
Show simple item record
Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H. M., Hackl, M. T., Kaplanian, M., Riedl, R., Luger, A., & Fürnsinn, C. (2017). Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. European Journal of Pharmacology, 798, 77–84. https://doi.org/10.1016/j.ejphar.2017.01.022
Abu Eid, S. et al. (2017) ‘Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents’, European Journal of Pharmacology, 798, pp. 77–84. Available at: https://doi.org/10.1016/j.ejphar.2017.01.022.
S. Abu Eid et al., “Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents,” European Journal of Pharmacology, vol. 798, pp. 77–84, 2017, doi: 10.1016/j.ejphar.2017.01.022.
ABU EID, Sameer, Michael ADAMS, Thomas SCHERER, Héctor Manuel TORRES-GÓMEZ, Martina Theresa HACKL, Mairam KAPLANIAN, Rainer RIEDL, Anton LUGER und Clemens FÜRNSINN, 2017. Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. European Journal of Pharmacology. 2017. Bd. 798, S. 77–84. DOI 10.1016/j.ejphar.2017.01.022
Abu Eid, Sameer, Michael Adams, Thomas Scherer, Héctor Manuel Torres-Gómez, Martina Theresa Hackl, Mairam Kaplanian, Rainer Riedl, Anton Luger, and Clemens Fürnsinn. 2017. “Emodin : A Compound with Putative Antidiabetic Potential, Deteriorates Glucose Tolerance in Rodents.” European Journal of Pharmacology 798: 77–84. https://doi.org/10.1016/j.ejphar.2017.01.022.
Abu Eid, Sameer, et al. “Emodin : A Compound with Putative Antidiabetic Potential, Deteriorates Glucose Tolerance in Rodents.” European Journal of Pharmacology, vol. 798, 2017, pp. 77–84, https://doi.org/10.1016/j.ejphar.2017.01.022.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.